Energy News / Shareholders Foundation, Inc.

NASDAQ: ALNY Long Term Investor Alert: Investigation of Potential Wrongdoing by Certain Directors of Alnylam Pharmaceuticals, Inc.

Via: ReleaseWire

Updated 11:15 AM CST, Thu, February 07,2019

An investigation on behalf of current long term investors in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares over possible breaches of fiduciary duty by certain officers and directors was announced and NASDAQ: ALNY stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWIRE) -- 02/07/2019 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Alnylam Pharmaceuticals, Inc.

Investors who are investors in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for investors in NASDAQ: ALNY stocks follows a lawsuit filed against Alnylam Pharmaceuticals, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: ALNY stocks, concerns whether certain Alnylam Pharmaceuticals, Inc. directors are liable in connection with the allegations made in that lawsuit.

The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that Alnylam overstated the efficacy and safety of its Onpattro (patisiran) lipid complex injection, and that as a result, Alnylam's public statements were materially false and misleading at all relevant times.

Cambrdige, MA based Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. Alnylam Pharmaceuticals, Inc. reported that its annual Total Revenue rose from $47.16 million in 2016 to $89.91 million in 2017 and that its Net loss increased from $410.11 million in 2016 to $490.87 million in 2017.

On September 7, 2017, Alnylam Pharmaceuticals, Inc. advised investors that the Company had stop giving doses of fitusiran, Alnylam's experimental hemophilia treatment, to patients enrolled in the Company's clinical studies, following the death of a patient who developed a blood clot.

In December 2017, Alnylam Pharmaceuticals, Inc. submitted its first new drug application and marketing authorization application for Onpattro (patisiran) to the U.S. Food and Drug Administration ("FDA"). Patisiran is an intravenously administered RNAi therapeutic targeting transthyretin ("TTR") for the treatment of hereditary ATTR amyloidosis. It is designed to target and silence specific messenger RNA, potentially blocking the production of TTR protein before it is made.

In August 2018, patisiran received FDA approval for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, having been reviewed by the FDA under Priority Review and previously granted Breakthrough Therapy and Orphan Drug Designations.

On September 12, 2018, Nomura/Instinet analyst Christopher Marai stated that a review document released by the U.S. Food and Drug Administration's ("FDA") Center for Drug Evaluation and Research "highlights greater risk" with respect to certain trials of Alnylams' ONPATTRO (patisiran) lipid complex injection, as well as "a limited market opportunity in TTRcardiomyopathy, and a potential platform safety risk." Specifically, Marai asserted that "[t]he document highlights FDA reviewers' concerns over cardiac deaths in patients treated with ONPATTRO and suggests that the drug should be limited to patients with polyneuropathy only (i.e., not patients with cardiac manifestations and polyneuropathy). Furthermore, we believe some comments on the lack of cardiac efficacy call into question claims made by [Alnylam] in this regard."

Those who purchased shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) have certain options and should contact the Shareholders Foundation.

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaq-alny-long-term-investor-alert-investigation-potential-1141677.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com